4d Molecular Therapeutics Share Price Today
(NASDAQ: FDMT)

Name: 4d Molecular Therapeutics Share Price Today (NASDAQ: FDMT) - 4d Molecular Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

4d Molecular Therapeutics share price is $4.16 & ₹361.79 as on 6 Mar 2025, 2.30 'hrs' IST

$4.16

▲

0.19

(4.79%)

Market is closed - opens 8 PM, 06 Mar 2025

View live 4d Molecular Therapeutics share price in Dollar and Rupees. Guide to invest in 4d Molecular Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in 4d Molecular Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

4d Molecular Therapeutics share price movements

Today's Low: $3.95
Today's High: $4.24
$4.16
5.05%
Downside
Day's Volatility :6.84%
Upside
1.89%
52 Weeks Low: $3.96
52 Weeks High: $36.25
$4.16
4.81%
Downside
52 Weeks Volatility :89.08%
Upside
88.52%

4d Molecular Therapeutics (FDMT) Returns

Period	4d Molecular Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	-41.79%	2.1%	0.0%
6 Months	-74.4%	-4.1%	0.0%
1 Year	-85.95%	2.2%	0.0%
3 Years	-70.7%	11.8%	-11.6%

4d Molecular Therapeutics (FDMT) Key Statistics

in dollars & INR

Previous Close	$3.97
Open	$4.0
Today's High	$4.24
Today's Low	$3.95
Market Capitalization	$191.4M
Today's Volume	$320.7K
52 Week High	$36.25
52 Week Low	$3.95
Revenue TTM	$37.0K
EBITDA	$-183.2M
Earnings Per Share (EPS)	$-2.85
Profit Margin	0.0%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-39.31%

How to invest in 4d Molecular Therapeutics Stock (FDMT) from India?

It is very easy for Indian residents to invest directly in 4d Molecular Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the 4d Molecular Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for 4d Molecular Therapeutics or FDMT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of 4d Molecular Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of 4d Molecular Therapeutics shares which would translate to 0.209 fractional shares of 4d Molecular Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like 4d Molecular Therapeutics, in just a few clicks!

Returns in 4d Molecular Therapeutics (FDMT) for Indian investors in Rupees

The 4d Molecular Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

4d Molecular Therapeutics investment value today

Current value as on today

₹19,683

Returns

₹80,317

(-80.32%)

Returns from 4d Molecular Therapeutics Stock

₹85,280 (-85.28%)

Dollar Returns

₹4,963 (+4.96%)

Indian investors sentiment towards 4d Molecular Therapeutics (FDMT)

32%

Period: Feb 3, 2025 to Mar 5, 2025. Change in 30 Days versus previous period

Search interest for 4d Molecular Therapeutics Stock from India on INDmoney has increased by 32% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in 4d Molecular Therapeutics

BlackRock Inc
10.65%
RA Capital Management, LLC
9.87%
Goldman Sachs Group Inc
9.25%
VR Adviser, LLC
6.39%
Vanguard Group Inc
6.19%
Bvf Inc
5.78%

Analyst Recommendation on 4d Molecular Therapeutics

Buy

94%Buy

5%Hold

0%Sell

Based on 17 Wall street analysts offering stock ratings for 4d Molecular Therapeutics(by analysts ranked 0 to 5 stars)

Based on 17 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on 4d Molecular Therapeutics Stock (FDMT)

What analysts predicted

Upside of 721.68%

Target:

$34.18

Current:

$4.16

Insights on 4d Molecular Therapeutics Stock (Ticker Symbol: FDMT)

Price Movement
In the last 7 days, FDMT stock has moved down by -17.3%
Decreasing Revenue
Revenue is down for the last 3 quarters, 28.0K → 3.0K (in $), with an average decrease of 61.1% per quarter
Decreasing Net Profit
Netprofit is down for the last 5 quarters, -10.25M → -43.84M (in $), with an average decrease of 62.1% per quarter
FDMT vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 62.3% return, outperforming this stock by 147.6%
FDMT vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 47.7% return, outperforming this stock by 117.5%
Price to Sales
ForFDMT every $1 of sales, investors are willing to pay $3970.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $13.8 for every $1 of sales.

FDMT 4d Molecular Therapeutics Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$7.0M	↓ 50.56%
Net Income	$-52.9M	↑ 454.28%
Net Profit Margin	-757.79%	↓ 690.2%

	FY20	Y/Y Change
Revenue	$13.6M	↑ 94.85%
Net Income	$-56.5M	↑ 6.8%
Net Profit Margin	-415.38%	↑ 342.41%

	FY21	Y/Y Change
Revenue	$18.0M	↑ 32.52%
Net Income	$-68.3M	↑ 20.79%
Net Profit Margin	-378.63%	↑ 36.75%

	FY22	Y/Y Change
Revenue	$3.1M	↓ 82.65%
Net Income	$-101.1M	↑ 47.99%
Net Profit Margin	-3.2K%	↓ 2851.67%

	FY23	Y/Y Change
Revenue	$20.7M	↑ 562.29%
Net Income	$-100.8M	↓ 0.24%
Net Profit Margin	-486.59%	↑ 2743.71%

	Q2 FY23	Q/Q Change
Revenue	$239.0K	↓ 19.8%
Net Income	$-29.6M	↑ 8.65%
Net Profit Margin	-12.4K%	↓ 3244.65%

	Q3 FY23	Q/Q Change
Revenue	$20.2M	↑ 8353.56%
Net Income	$-10.3M	↓ 65.37%
Net Profit Margin	-50.76%	↑ 12340.87%

	Q4 FY23	Q/Q Change
Revenue	$-19.0K	↓ 100.09%
Net Income	$-32.3M	↑ 214.77%
Net Profit Margin	169.9K%	↑ 169961.29%

	Q1 FY24	Q/Q Change
Revenue	$28.0K	↓ 247.37%
Net Income	$-32.4M	↑ 0.37%
Net Profit Margin	-115.7K%	↓ 285628.39%

	Q2 FY24	Q/Q Change
Revenue	$5.0K	↓ 82.14%
Net Income	$-35.0M	↑ 7.88%
Net Profit Margin	-699.1K%	↓ 583342.14%

	Q3 FY24	Q/Q Change
Revenue	$3.0K	↓ 40.0%
Net Income	$-43.8M	↑ 25.43%
Net Profit Margin	-1.5M%	↓ 762373.33%

	FY19	Y/Y Change
Profit	$-31.7M	↓ 324.57%

	FY20	Y/Y Change
Profit	$-39.4M	↑ 24.25%

	FY21	Y/Y Change
Profit	$18.0M	↓ 145.75%

	FY22	Y/Y Change
Profit	$3.1M	↓ 82.65%

	FY23	Y/Y Change
Profit	$-76.4M	↓ 2540.81%

	Q2 FY23	Q/Q Change
Profit	$-1.2M	↑ 6.73%

	Q3 FY23	Q/Q Change
Profit	$18.8M	↓ 1681.83%

	Q4 FY23	Q/Q Change
Profit	$-4.3M	↓ 122.62%

	Q1 FY24	Q/Q Change
Profit	$-1.6M	↓ 63.2%

	Q2 FY24	Q/Q Change
Profit	$-1.6M	↑ 3.38%

	Q3 FY24	Q/Q Change
Profit	$3.0K	↓ 100.19%

	FY19	Y/Y Change
Operating Cash Flow	$-36.7M	↑ 125.89%
Investing Cash Flow	$-3.2M	↑ 673.67%
Financing Cash Flow	$-2.2M	↓ 102.6%

	FY20	Y/Y Change
Operating Cash Flow	$-50.9M	↑ 38.68%
Investing Cash Flow	$-1000.0K	↓ 68.78%
Financing Cash Flow	$279.0M	↓ 12809.93%

	FY21	Y/Y Change
Operating Cash Flow	$-69.1M	↑ 35.8%
Investing Cash Flow	$-172.7M	↑ 17168.0%
Financing Cash Flow	$118.1M	↓ 57.67%

	FY22	Y/Y Change
Operating Cash Flow	$-86.7M	↑ 25.39%
Investing Cash Flow	$-17.1M	↓ 90.13%
Financing Cash Flow	$3.1M	↓ 97.39%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$-22.1M	↓ 20.93%
Investing Cash Flow	$49.3M	↑ 14.28%
Financing Cash Flow	$130.5M	↑ 1087.18%

4d Molecular Therapeutics Technicals Summary

Sell

Neutral

Buy

4d Molecular Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

4d Molecular Therapeutics (FDMT) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
4d Molecular Therapeutics Inc	-32.94%	-74.4%	-85.95%	-70.7%	-90.2%
Regeneron Pharmaceuticals, Inc.	1.3%	-41.29%	-30.51%	9.2%	42.38%
Beone Medicines Ltd	15.19%	34.31%	61.3%	43.16%	68.1%
Vertex Pharmaceuticals Incorporated	3.37%	3.77%	18.06%	106.43%	121.36%
Alnylam Pharmaceuticals, Inc.	-11.52%	-3.4%	62.32%	49.04%	120.93%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
4d Molecular Therapeutics Inc	NA	NA	NA	-3.59	-0.39	-0.26	NA	11.15
Regeneron Pharmaceuticals, Inc.	17.85	17.85	1.03	43.09	0.16	0.07	0.01	273.57
Beone Medicines Ltd	NA	NA	NA	1.43	-0.19	-0.06	NA	31.22
Vertex Pharmaceuticals Incorporated	32.84	NA	1.33	18.07	-0.03	0.13	NA	63.87
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	0.57	-15.01	-0.03	NA	0.52

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
4d Molecular Therapeutics Inc	Buy	$191.4M	-90.2%	NA	0.0%
Regeneron Pharmaceuticals, Inc.	Buy	$74.9B	42.38%	17.85	31.07%
Beone Medicines Ltd	NA	$28.5B	68.1%	NA	-16.92%
Vertex Pharmaceuticals Incorporated	Buy	$124.1B	121.36%	32.84	-4.86%
Alnylam Pharmaceuticals, Inc.	Buy	$31.5B	120.93%	NA	-12.37%

About 4d Molecular Therapeutics

4D Molecular Therapeutics, Inc., a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology. Its product pipeline includes 4D-150, which is in phase 1/2 clinical trial for the treatment of wet age-related macular degeneration; and is in phase 1/2 clinical trial for the treatment of diabetic macular edema. The company develops 4D-125, which is in phase 1/2 clinical trial for the treatment of x-linked retinitis pigmentosa; 4D-110, which is in phase 1/2 clinical trial for the treatment of choroideremia; 4D-710, which is in phase 1/2 clinical trial for the treatment cystic fibrosis lung disease; and 4D-310 to treat fabry disease cardiomyopathy and is in phase 1/2 clinical trial. In addition, its product candidates comprises 4D-175, which is in pre-clinical development for the treatment for geographic trophy; and 4D-725 to treat alpha-1 antitrypsin deficiency lung disease and is in pre-clinical development. The company has collaboration and licensing agreements with Arbor Biotechnologies, Inc.; Astellas Gene Therapies, Inc; uniQure biopharma B.V.; and Cystic Fibrosis Foundation. 4D Molecular Therapeutics, Inc. was founded in 2013 and is headquartered in Emeryville, California.

Organization	4d Molecular Therapeutics
Employees	0
CEO	Dr. John F. Milligan Ph.D.
Industry	Healthcare

Management People of 4d Molecular Therapeutics

Name	Title
Dr. John F. Milligan Ph.D.	Executive Chairman
Dr. Fariborz Kamal Ph.D.	President & COO
Dr. Noriyuki Kasahara M.D., Ph.D.	Chief Scientific Officer
Dr. Robert Y. Kim M.B.A., M.D.	Chief Medical Officer
Ms. Theresa Janke	Co-Founder & Chief of Staff
Dr. Scott P. Bizily J.D., Ph.D.	Chief Legal Officer & Corporate Secretary
Dr. An Song Ph.D.	Chief Development Officer
Dr. Alan H. Cohen FAAAAI, FAAP, FACAAI, FCCP, M.D.	Senior VP & Therapeutic Area Head of Pulmonology
Mr. Christopher Paul Simms	Chief Commercial Officer
Ms. Karen S. Carothers	Controller

Important FAQs about investing in FDMT Stock from India :

What is 4d Molecular Therapeutics share price today?

4d Molecular Therapeutics share price today stands at $4.16, Open: $4.00 ; Previous Close: $3.97 ; High: $4.24 ; Low: $3.95 ; 52 Week High: $36.25 ; 52 Week Low: $3.96.

The stock opens at $4.00, after a previous close of $3.97. The stock reached a daily high of $4.24 and a low of $3.95, with a 52-week high of $36.25 and a 52-week low of $3.96.

Can Indians buy 4d Molecular Therapeutics shares?

Yes, Indians can invest in the 4d Molecular Therapeutics (FDMT) from India.

With INDmoney, you can buy 4d Molecular Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy 4d Molecular Therapeutics at zero transaction cost.

How can I buy 4d Molecular Therapeutics shares from India?

It is very easy to buy 4d Molecular Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of 4d Molecular Therapeutics (FDMT) be purchased?

Yes, you can buy fractional shares of 4d Molecular Therapeutics with INDmoney app.

What are the documents required to start investing in 4d Molecular Therapeutics stocks?

To start investing in 4d Molecular Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.